Table 1.

Summary of positive phase 3 clinical trials of angiogenic inhibitors in patients with advanced hepatocellular carcinoma (HCC)

Molecules	Trial	N	Population	mOS	mPFS	ORR	DCR	Comments
Sorafenib	SHARP [18]	602	First-line Versus placebo	10.7 m	5.5 m	2%	43%
	ASIAPACIFIC [19]	226	First-line Versus placebo	6.5 m	2.8 m	3.3%	35.3%
Lenvatinib	REFLECT [20]	954	First-line Versus sorafenib	13.6 m	8.9 m	24.1, 1%CR	75.5%
Regorafenib	RESORCE [21]	573	Second-line Versus placebo	10.6 m	3.2 m	11%	65%	Exclusion of patients previously intolerant to sorafenib
Cabozantinib	CELESTIAL [22]	707	Second or third-line Versus placebo	10.2 m	5.2 m	4%	64%	Inclusion of patients previously intolerant to sorafenib
Ramucirumab	REACH-2 (35)	292	Second-line Versus placebo	8.5 m	2.8 m	4.6%	59.9%	Inclusion of patients with poor prognosis based on high alpha-foeto-protein levels

CR complete response; DCR disease control rate; m months; mOS median overall survival; mPFS median progression-free-survival; N number of randomized patients; ORR objective response rate